表紙
市場調査レポート

PharmaPoint:全身性エリテマトーデス・ループス腎炎 - 世界における医薬品の予測と市場分析

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

発行 GlobalData 商品コード 296461
出版日 ページ情報 英文 323 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
PharmaPoint:全身性エリテマトーデス・ループス腎炎 - 世界における医薬品の予測と市場分析 PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日: 2015年02月27日 ページ情報: 英文 323 Pages
概要

ループス治療薬市場は、ジェネリック医薬品に独占されています。全身性エリテマトーデス(SLE)治療薬市場において、販売承認を獲得している唯一の医薬品が、GlaxoSmithKlineのベンリスタです。

当レポートでは、世界における全身性エリテマトーデス(SLE)・ループス腎炎(LN)治療薬市場について調査分析し、疾患の概要、収益実績と予測、主要トピック(戦略的競合企業の評価、市場の特性、アンメットニーズ、臨床試験マッピングなど)、パイプライン分析、現在/将来の市場競合分析(促進要因・抑制要因、課題など)を提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 予後
  • 生活の質(QOL)
  • 症状

第4章 疫学

  • 危険因子と併存疾患
    • 女性は、男性よりSLEの発症リスクが高い
    • 白人は、他の民族よりSLEの発症リスクが低い
    • 家族歴は、SLEの発症リスクの増加に関連している
    • 特定の職業と環境暴露はSLEを誘発
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
  • 利用した情報源
  • 利用しなかった情報源
  • 予測の前提条件と手法
  • SLEの疫学予測
  • 議論

第5章 疾患の管理

  • 診断の概要
  • 治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第6章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • 抗マラリア性治療
    • ステロイド
    • メトトレキサート
    • ミコフェノール酸モフェチル
    • シクロホスファミド
    • アザチオプリン
    • カルシニューリン阻害薬
    • ベンリスタ(belimumab)
    • リツキサン(rituximab)

第7章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • 機会

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望な薬剤

第9章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • GlaxoSmithKline
    • Roche
    • UCB
    • Eli Lilly and Company
    • Bristol-Myers Squibb
    • Anthera Pharmaceuticals
    • ImmuPharma
    • Merck Serono

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC009EPIDR

The lupus therapeutics market is dominated by generics and GlaxoSmithKline's Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta's launch, patients' uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and seven promising biological therapies have the potential to enter the SLE and LN market during the 2012-2022 forecast period. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

Highlights

Key Questions Answered

  • What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
  • What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
  • What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
  • What are the significant unmet needs in the SLE and LN markets?
  • What are the remaining opportunities in the SLE and LN markets?

Key Findings

  • The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKline's Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
  • R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
  • The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.

Scope

  • Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Prognosis
  • 3.3. Quality of Life
  • 3.4. Symptoms

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. Women are at a higher risk of developing SLE than men
    • 4.1.2. Caucasians are at lower risk of developing SLE than other ethnicities
    • 4.1.3. Familial history has been associated with an increased risk of developing SLE
    • 4.1.4. Certain occupational and environmental exposures trigger SLE
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Japan
  • 4.3. Forecast Methodology
  • 4.4. Sources Used
    • 4.4.1. US
    • 4.4.2. France
    • 4.4.3. Germany
    • 4.4.4. Italy
    • 4.4.5. Spain
    • 4.4.6. UK
    • 4.4.7. Japan
  • 4.5. Sources Not Used
    • 4.5.1. US
    • 4.5.2. 5EU
    • 4.5.3. Japan
  • 4.6. Forecast Assumptions and Methods
    • 4.6.1. US
    • 4.6.2. 5EU
    • 4.6.3. Japan
  • 4.7. Epidemiological Forecast of SLE (2012-2022)
    • 4.7.1. Diagnosed Prevalent Cases of SLE
    • 4.7.2. Age-Specific Prevalent Cases of SLE
    • 4.7.3. Sex-Specific Prevalent Cases of Diagnosed SLE
    • 4.7.4. Age-Standardized Prevalence of SLE
    • 4.7.5. Diagnosed Prevalent Cases of LN
    • 4.7.6. Prevalent Cases of LN, Segmented by Class
  • 4.8. Discussion
    • 4.8.1. Conclusions on Epidemiology Trends
    • 4.8.2. Limitations of the Analysis
    • 4.8.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. SLE Diagnosis
    • 5.1.2. LN Diagnosis
  • 5.2. Treatment Overview
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Antimalarial Therapy (numerous brand names)
    • 6.3.2. Steroids (numerous brand names)
    • 6.3.3. Methotrexate (numerous brand names)
    • 6.3.4. Mycophenolate Mofetil (numerous brand names)
    • 6.3.5. Cyclophosphamide (numerous brand names)
    • 6.3.6. Azathioprine (numerous brand names)
    • 6.3.7. Calcineurin Inhibitors (numerous brand names)
    • 6.3.8. Benlysta (belimumab)
    • 6.3.9. Rituxan (rituximab)
    • 6.3.10. Minor Therapeutic Classes

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Unmet Needs
    • 7.2.1. Efficacious Treatments with Reduced Side Effects
    • 7.2.2. Management of LN
    • 7.2.3. Improvement in Patients' Mortality
    • 7.2.4. Management of Lupus Comorbidities
    • 7.2.5. Sensitive and Reliable Biomarkers
    • 7.2.6. Physicians' Education and Public Awareness of SLE
    • 7.2.7. Unmet Needs Gap Analysis
  • 7.3. Opportunities
    • 7.3.1. Efficacious and Safe Therapies
    • 7.3.2. Therapies Targeting LN Patients
    • 7.3.3. Treatments for Common Lupus Comorbidities
    • 7.3.4. Discovery of Biomarkers

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Therapy Type
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Blisibimod (A-623)
    • 8.3.2. Atacicept
    • 8.3.3. Epratuzumab
    • 8.3.4. Lupuzor (rigerimod)
    • 8.3.5. Orencia (abatacept)
    • 8.3.6. Sifalimumab (MEDI-545)
    • 8.3.7. PF-04236921
    • 8.3.8. Anifrolumab (MEDI-546)
    • 8.3.9. Lulizumab Pegol (BMS-931699)
    • 8.3.10. BIIB023
    • 8.3.11. Voclosporin
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. GlaxoSmithKline
    • 9.3.2. Roche
    • 9.3.3. UCB
    • 9.3.4. Bristol-Myers Squibb
    • 9.3.5. Anthera
    • 9.3.6. ImmuPharma
    • 9.3.7. Merck Serono
    • 9.3.8. AstraZeneca
    • 9.3.9. Pfizer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed SLE and LN Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analysts
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of SLE
  • Table 2: Risk Factors Associated with SLE
  • Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982)
  • Table 4: Sources of Prevalence Data Used in this Analysis
  • Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Select Years 2012-2022
  • Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
  • Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012
  • Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Select Years 2012-2022
  • Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012
  • Table 10: 1997 Updated ACR Criteria for Classification of SLE
  • Table 11: The SLICC Clinical and Immunologic Criteria for Classification of SLE
  • Table 12: WHO and ISN/RPS classifications of LN
  • Table 13: Treatment Guidelines for SLE and LN
  • Table 14: Most Prescribed Drugs for SLE and LN by Class in the Global Markets
  • Table 15: Leading Treatments for SLE and LN, 2015
  • Table 16: Product Profile - Hydroxychloroquine
  • Table 17: Antimalarial Therapy SWOT Analysis, 2015
  • Table 18: Global SLE Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
  • Table 19: Global LN Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
  • Table 20: Product Profile - Steroids
  • Table 21: Steroids SWOT Analysis, 2015
  • Table 22: Global SLE Sales Forecasts ($m) for Steroid Therapy, 2012-2022
  • Table 23: Global LN Sales Forecasts ($m) for Steroid Therapy, 2012-2022
  • Table 24: Product Profile - Methotrexate
  • Table 25: Methotrexate SWOT Analysis, 2015
  • Table 26: Global SLE Sales Forecasts ($m) for MTX, 2012-2022
  • Table 27: Global LN Sales Forecasts ($m) for MTX, 2012-2022
  • Table 28: Product Profile - Mycophenolate Mofetil
  • Table 29: Mycophenolate Mofetil SWOT Analysis, 2015
  • Table 30: Global SLE Sales Forecasts ($m) for MMF, 2012-2022
  • Table 31: Global LN Sales Forecasts ($m) for MMF, 2012-2022
  • Table 32: Product Profile - Cyclophosphamide
  • Table 33: Cyclophosphamide SWOT Analysis, 2015
  • Table 34: Global SLE Sales Forecasts ($m) for CYC, 2012-2022
  • Table 35: Global LN Sales Forecasts ($m) for CYC, 2012-2022
  • Table 36: Product Profile - Azathioprine
  • Table 37: Azathioprine SWOT Analysis, 2015
  • Table 38: Global SLE Sales Forecasts ($m) for AZA, 2012-2022
  • Table 39: Global LN Sales Forecasts ($m) for AZA, 2012-2022
  • Table 40: Product Profile - Calcineurin Inhibitors
  • Table 41: Calcineurin Inhibitors SWOT Analysis, 2015
  • Table 42: Global SLE Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
  • Table 43: Global LN Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
  • Table 44: Product Profile - Benlysta
  • Table 45: Benlysta SWOT Analysis, 2015
  • Table 46: Global SLE Sales Forecasts ($m) for Benlysta, 2012-2022
  • Table 47: Global LN Sales Forecasts ($m) for Benlysta, 2012-2022
  • Table 48: Product Profile - Rituxan
  • Table 49: Rituxan SWOT Analysis, 2015
  • Table 50: Global SLE Sales Forecasts ($m) for Rituxan, 2012-2022
  • Table 51: Global LN Sales Forecasts ($m) for Rituxan, 2012-2022
  • Table 52: Summary of Minor Therapeutic Classes in SLE and LN, 2015
  • Table 53: Overall Unmet Needs in SLE and LN - Current Level of Attainment
  • Table 54: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2015
  • Table 55: Drugs in Late-Stage Clinical Development for SLE and LN, 2015
  • Table 56: Product Profile - Blisibimod
  • Table 57: Blisibimod SWOT Analysis, 2015
  • Table 58: Global SLE Sales Forecasts ($m) for Blisibimod, 2012-2022
  • Table 59: Global LN Sales Forecasts ($m) for Blisibimod, 2012-2022
  • Table 60: Product Profile - Atacicept
  • Table 61: Atacicept SWOT Analysis, 2015
  • Table 62: Global SLE Sales Forecasts ($m) for Atacicept, 2012-2022
  • Table 63: Global LN Sales Forecasts ($m) for Atacicept, 2012-2022
  • Table 64: Product Profile - Epratuzumab
  • Table 65: Epratuzumab SWOT Analysis, 2015
  • Table 66: Global SLE Sales Forecasts ($m) for Epratuzumab, 2012-2022
  • Table 67: Global LN Sales Forecasts ($m) for Epratuzumab, 2012-2022
  • Table 68: Product Profile - Lupuzor
  • Table 69: Lupuzor SWOT Analysis, 2015
  • Table 70: Global SLE Sales Forecasts ($m) for Lupuzor, 2012-2022
  • Table 71: Global LN Sales Forecasts ($m) for Lupuzor, 2012-2022
  • Table 72: Product Profile - Orencia
  • Table 73: Orencia SWOT Analysis, 2015
  • Table 74: Global SLE Sales Forecasts ($m) for Orencia, 2012-2022
  • Table 75: Global LN Sales Forecasts ($m) for Orencia, 2012-2022
  • Table 76: Product Profile - Sifalimumab
  • Table 77: Sifalimumab SWOT Analysis, 2015
  • Table 78: Global SLE Sales Forecasts ($m) for Sifalimumab, 2012-2022
  • Table 79: Global LN Sales Forecasts ($m) for Sifalimumab, 2012-2022
  • Table 80: Product Profile - PF-04236921
  • Table 81: PF-04236921 SWOT Analysis, 2015
  • Table 82: Global SLE Sales Forecasts ($m) for PF-04236921, 2012-2022
  • Table 83: Global LN Sales Forecasts ($m) for PF-04236921, 2012-2022
  • Table 84: Product Profile - Anifrolumab
  • Table 85: Anifrolumab SWOT Analysis, 2015
  • Table 86: Product Profile - Lulizumab Pegol
  • Table 87: Lulizumab Pegol SWOT Analysis, 2015
  • Table 88: Product Profile - BIIB023
  • Table 89: BIIB023 SWOT Analysis, 2015
  • Table 90: Product Profile - Voclosporin
  • Table 91: Voclosporin SWOT Analysis, 2015
  • Table 92: Drugs in Early-stage Clinical Development for SLE and LN, 2015
  • Table 93: Key Companies in the SLE and LN Market, 2015
  • Table 94: GSK's SLE and LN Portfolio Assessment, 2015
  • Table 95: GlaxoSmithKline SWOT Analysis, 2015
  • Table 96: Roche's SLE and LN Portfolio Assessment, 2015
  • Table 97: Roche SWOT Analysis, 2015
  • Table 98: UCB's SLE and LN Portfolio Assessment, 2015
  • Table 99: UCB SWOT Analysis, 2015
  • Table 100: BMS's SLE and LN Portfolio Assessment, 2015
  • Table 101: BMS SWOT Analysis, 2015
  • Table 102: Anthera's SLE and LN Portfolio Assessment, 2015
  • Table 103: Anthera SWOT Analysis, 2015
  • Table 104: ImmuPharma's SLE and LN Portfolio Assessment, 2015
  • Table 105: ImmuPharma SWOT Analysis, 2015
  • Table 106: Merck Serono's SLE and LN Portfolio Assessment, 2015
  • Table 107: Merck Serono SWOT Analysis, 2015
  • Table 108: AstraZeneca's SLE and LN Portfolio Assessment, 2015
  • Table 109: AstraZeneca SWOT Analysis, 2015
  • Table 110: Pfizer's SLE and LN Portfolio Assessment, 2015
  • Table 111: Pfizer SWOT Analysis, 2015
  • Table 112: Global Sales Forecasts ($m) for SLE, 2012-2022
  • Table 113: Global Sales Forecasts ($m) for LN, 2012-2022
  • Table 114: SLE and LN Market - Global Drivers and Barriers, 2012-2022
  • Table 115: Sales Forecasts ($m) for SLE in the US, 2012-2022
  • Table 116: Sales Forecasts ($m) for LN in the US, 2012-2022
  • Table 117: Key Events Impacting Sales for SLE and LN in the US, 2012-2022
  • Table 118: SLE and LN Market in the US - Drivers and Barriers, 2012-2022
  • Table 119: Sales Forecasts ($m) for SLE in France, 2012-2022
  • Table 120: Sales Forecasts ($m) for LN in France, 2012-2022
  • Table 121: Key Events Impacting Sales for SLE and LN in France, 2012-2022
  • Table 122: SLE and LN Market in France - Drivers and Barriers, 2012-2022
  • Table 123: Sales Forecasts ($m) for SLE in Germany, 2012-2022
  • Table 124: Sales Forecasts ($m) for LN in Germany, 2012-2022
  • Table 125: Key Events Impacting Sales for SLE and LN in Germany, 2012-2022
  • Table 126: SLE and LN Market in Germany - Drivers and Barriers, 2012-2022
  • Table 127: Sales Forecasts ($m) for SLE in Italy, 2012-2022
  • Table 128: Sales Forecasts ($m) for LN in Italy, 2012-2022
  • Table 129: Key Events Impacting Sales for SLE and LN in Italy, 2012-2022
  • Table 130: SLE and LN Market in Italy - Drivers and Barriers, 2012-2022
  • Table 131: Sales Forecasts ($m) for SLE in Spain, 2012-2022
  • Table 132: Sales Forecasts ($m) for LN in Spain, 2012-2022
  • Table 133: Key Events Impacting Sales for SLE and LN in Spain, 2012-2022
  • Table 134: SLE and LN Market in Spain - Drivers and Barriers, 2012-2022
  • Table 135: Sales Forecasts ($m) for SLE in the UK, 2012-2022
  • Table 136: Sales Forecasts ($m) for LN in the UK, 2012-2022
  • Table 137: Key Events Impacting Sales for SLE and LN in the UK, 2012-2022
  • Table 138: SLE and LN Market in the UK - Drivers and Barriers, 2012-2022
  • Table 139: Sales Forecasts ($m) for SLE in Japan, 2012-2022
  • Table 140: Sales Forecasts ($m) for LN in Japan, 2012-2022
  • Table 141: Key Events Impacting Sales for SLE and LN in Japan, 2012-2022
  • Table 142: SLE and LN Market in Japan - Drivers and Barriers, 2012-2022
  • Table 143: Key Launch Dates
  • Table 144: Key Patent Expiries
  • Table 145: Number of Physicians Surveyed by Country

List of Figures

  • Figure 1: Overview of the Etiology and Pathogenesis of SLE
  • Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
  • Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 2012-2022
  • Figure 4: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
  • Figure 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012
  • Figure 6: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012
  • Figure 7: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 2012-2022
  • Figure 8: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012
  • Figure 9: Overview of the Treatment Management of SLE
  • Figure 10: SLE and LN Therapeutics - Clinical Trials by Type of Therapy and Development Stage, January 2015
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022
  • Figure 12: Company Portfolio Gap Analysis in SLE and LN, 2012-2022
  • Figure 13: Global Sales for SLE and LN by Region, 2012-2022
  • Figure 14: Sales for SLE in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
  • Figure 15: Sales for LN in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
  • Figure 16: Sales for SLE and LN in the US by Drug Class, 2012-2022
  • Figure 17: Sales for SLE and LN in France by Drug Class, 2012-2022
  • Figure 18: Sales for SLE and LN in Germany by Drug Class, 2012-2022
  • Figure 19: Sales for SLE and LN in Italy by Drug Class, 2012-2022
  • Figure 20: Sales for SLE and LN in Spain by Drug Class, 2012-2022
  • Figure 21: Sales for SLE and LN in the UK by Drug Class, 2012-2022
  • Figure 22: Sales for SLE and LN in Japan by Drug Class, 2012-2022
Back to Top